HRP20140899T1 - Anti-cxcr4 antitijela i njihova upotreba za lijeäśenje karcinoma - Google Patents
Anti-cxcr4 antitijela i njihova upotreba za lijeäśenje karcinoma Download PDFInfo
- Publication number
- HRP20140899T1 HRP20140899T1 HRP20140899AT HRP20140899T HRP20140899T1 HR P20140899 T1 HRP20140899 T1 HR P20140899T1 HR P20140899A T HRP20140899A T HR P20140899AT HR P20140899 T HRP20140899 T HR P20140899T HR P20140899 T1 HRP20140899 T1 HR P20140899T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- sequence
- cdr
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13677208P | 2008-10-01 | 2008-10-01 | |
| EP08305631A EP2172485A1 (en) | 2008-10-01 | 2008-10-01 | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
| US17374309P | 2009-04-29 | 2009-04-29 | |
| PCT/EP2009/062787 WO2010037831A1 (en) | 2008-10-01 | 2009-10-01 | Anti cxcr4 antibodies and their use for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140899T1 true HRP20140899T1 (hr) | 2014-11-07 |
Family
ID=40361774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140899AT HRP20140899T1 (hr) | 2008-10-01 | 2009-10-01 | Anti-cxcr4 antitijela i njihova upotreba za lijeäśenje karcinoma |
Country Status (28)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
| EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
| JP2014504147A (ja) * | 2010-10-27 | 2014-02-20 | ピエール、ファーブル、メディカマン | Ｈｉｖの治療用抗体 |
| US20140120555A1 (en) * | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
| WO2012178137A1 (en) | 2011-06-24 | 2012-12-27 | Gillies Stephen D | Light chain immunoglobulin fusion proteins and methods of use thereof |
| AR087363A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |
| AR087364A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres |
| NL2010658C2 (en) * | 2013-04-18 | 2014-10-21 | Bosch Gmbh Robert | Thermostat for a hvac. |
| JP6506280B2 (ja) * | 2013-08-02 | 2019-05-08 | ファイザー・インク | 抗ｃｘｃｒ４抗体および抗体−薬剤コンジュゲート |
| JP2016530895A (ja) | 2013-09-23 | 2016-10-06 | ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ | 動物細胞を遺伝子改変する改良された方法 |
| AR104413A1 (es) * | 2015-04-27 | 2017-07-19 | Pf Medicament | Anticuerpo de igf-1r y su utilización para diagnosticar cáncer |
| US20180179282A1 (en) | 2015-06-12 | 2018-06-28 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| CA3004498A1 (en) * | 2015-11-09 | 2017-05-18 | Neil R. Cashman | Amyloid beta epitopes and antibodies thereto |
| JP7448174B2 (ja) | 2015-11-09 | 2024-03-12 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体 |
| EP3408378B1 (en) | 2016-01-25 | 2022-01-12 | NantCell, Inc. | Nk cells with altered cxcl12/cxcr4 signaling |
| JPWO2017203799A1 (ja) * | 2016-05-25 | 2019-02-28 | 株式会社東芝 | エネルギー管理装置、管理システム、消費電力監視方法及びプログラム |
| CN116903741A (zh) | 2016-06-20 | 2023-10-20 | 科马布有限公司 | 特异性结合于pd-l1的抗体或其抗原结合片段及其用途 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| CA3052070A1 (en) * | 2017-01-31 | 2018-08-09 | Msm Protein Technologies Inc. | Anti-cxcr4 antibodies |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| US20230181635A1 (en) | 2018-03-13 | 2023-06-15 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy |
| CN110804100A (zh) * | 2019-11-01 | 2020-02-18 | 中国人民解放军陆军特色医学中心 | 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| CN112521500B (zh) * | 2020-12-25 | 2022-06-24 | 暨南大学 | 与cxcr4结合的亲和力成熟结合蛋白及应用 |
| CN112661845B (zh) * | 2020-12-25 | 2022-06-21 | 暨南大学 | 与cxcr4结合的亲和力成熟结合蛋白及其应用 |
| WO2025049591A1 (en) * | 2023-08-28 | 2025-03-06 | Regeneron Pharmaceuticals, Inc. | Anti-cxcr4 antibodies and uses thereof |
| CN117003876B (zh) * | 2023-08-31 | 2024-06-18 | 恺佧生物科技(上海)有限公司 | 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6949243B1 (en) * | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
| US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
| WO2006086883A1 (en) * | 2005-02-16 | 2006-08-24 | Universite De Montreal | Biosensors for monitoring receptor-mediated g-protein activation |
| EP1871807B1 (en) * | 2005-02-18 | 2012-11-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against cxcr4 and methods of use thereof |
| CA2724409A1 (en) * | 2008-05-14 | 2009-11-19 | Eli Lilly And Company | Anti-cxcr4 antibodies |
-
2008
- 2008-10-01 EP EP08305631A patent/EP2172485A1/en not_active Withdrawn
-
2009
- 2009-09-30 TW TW98133164A patent/TWI469792B/zh not_active IP Right Cessation
- 2009-10-01 AU AU2009299787A patent/AU2009299787B2/en not_active Ceased
- 2009-10-01 GE GEAP200912211A patent/GEP20146084B/en unknown
- 2009-10-01 KR KR1020117009556A patent/KR101671039B1/ko not_active Expired - Fee Related
- 2009-10-01 SI SI200931016T patent/SI2342233T1/sl unknown
- 2009-10-01 AR ARP090103802A patent/AR073748A1/es unknown
- 2009-10-01 DK DK09744645.4T patent/DK2342233T3/da active
- 2009-10-01 RS RSP20140515 patent/RS53578B1/sr unknown
- 2009-10-01 UA UAA201105412A patent/UA102867C2/uk unknown
- 2009-10-01 CN CN200980144491.4A patent/CN102209730B/zh not_active Expired - Fee Related
- 2009-10-01 JP JP2011529559A patent/JP5723279B2/ja not_active Expired - Fee Related
- 2009-10-01 RU RU2011115559/10A patent/RU2573897C2/ru not_active IP Right Cessation
- 2009-10-01 PL PL09744645T patent/PL2342233T3/pl unknown
- 2009-10-01 CA CA2738782A patent/CA2738782C/en not_active Expired - Fee Related
- 2009-10-01 HR HRP20140899AT patent/HRP20140899T1/hr unknown
- 2009-10-01 ES ES09744645.4T patent/ES2503732T3/es active Active
- 2009-10-01 EP EP09744645.4A patent/EP2342233B1/en active Active
- 2009-10-01 PT PT97446454T patent/PT2342233E/pt unknown
- 2009-10-01 WO PCT/EP2009/062787 patent/WO2010037831A1/en not_active Ceased
- 2009-10-01 NZ NZ592363A patent/NZ592363A/xx not_active IP Right Cessation
- 2009-10-01 MA MA33784A patent/MA32928B1/fr unknown
- 2009-10-01 MX MX2011003509A patent/MX2011003509A/es active IP Right Grant
- 2009-10-01 BR BRPI0920531-4A patent/BRPI0920531A2/pt not_active IP Right Cessation
-
2010
- 2010-03-30 US US12/749,891 patent/US8557964B2/en not_active Expired - Fee Related
-
2011
- 2011-03-31 IL IL212066A patent/IL212066A/en not_active IP Right Cessation
- 2011-04-01 CL CL2011000730A patent/CL2011000730A1/es unknown
- 2011-04-20 ZA ZA2011/02969A patent/ZA201102969B/en unknown
- 2011-06-23 US US13/167,329 patent/US20110287451A1/en not_active Abandoned
- 2011-06-23 US US13/167,321 patent/US20110294156A1/en not_active Abandoned
-
2013
- 2013-09-13 US US14/025,875 patent/US9388248B2/en not_active Expired - Fee Related
-
2014
- 2014-09-24 CY CY20141100778T patent/CY1115572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140899T1 (hr) | Anti-cxcr4 antitijela i njihova upotreba za lijeäśenje karcinoma | |
| US11174316B2 (en) | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof | |
| US20230295300A1 (en) | Antibodies specific to delta 1 chain of t cell receptor | |
| JP7020909B2 (ja) | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 | |
| HRP20140502T1 (hr) | Humanizirana anti-cxcr4 antitijela za lijeäśenje karcinoma | |
| HRP20150887T1 (hr) | Nova antitijela koja inhibiraju dimerizaciju c-met te njihova upotreba | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| RU2011124751A (ru) | Антитело против смет | |
| US20220340673A1 (en) | Antibody targeting bcma, bispecific antibody, and use thereof | |
| JP2012504401A5 (cg-RX-API-DMAC7.html) | ||
| JP2018532383A5 (cg-RX-API-DMAC7.html) | ||
| JP7642096B2 (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| US20250179195A1 (en) | Anti-flt3 antibodies and compositions | |
| Luan et al. | A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity | |
| JP2025157456A (ja) | Ｃｄ４７に対する単一ドメイン抗体及びその用途 | |
| US12084500B2 (en) | Antibodies specific to delta 1 chain of T cell receptor | |
| WO2022242663A1 (en) | Anti-tigit antibodies and their use | |
| CN113549152B (zh) | 一种抗basigin人源化抗体及其应用 | |
| CN118146374A (zh) | 新颖pd-1结合域 | |
| CN118891287A (zh) | 抗cd73的抗体及其应用 | |
| Bernareggi et al. | Introductory Remarks for the Diagnostic and Therapeutic Applications of Monoclonal Antibodies and Various Formats | |
| HK1190161B (en) | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |